Mark J. Ratain
Mark J. Ratain, MD, is an expert in the use of investigational agents to treat advanced solid tumors. He also has a special interest in pharmacogenetics — the study of how genetic variation affects the body's response to medications. Dr. Ratain’s research focuses on the development of new oncology drugs and developing diagnostic tests in order to create individualized anticancer therapies based on each person’s genetic makeup.
He is an international leader in phase I clinical trials, pharmacogenetics and clinical trial methodology. He has more than 300 original publications and leads the UChicago’s phase I oncology trials program. In addition, he serves as director of the Center for Personalized Therapeutics and is chief hospital pharmacologist for the University of Chicago Medical Center.